Hyperbaric Oxygen Therapy in Acute Ischemic Stroke Ischemic Stroke Recovery (Pro00061930)

Last updated: November 19, 2023
Sponsor: LCMC Health
Overall Status: Active - Recruiting

Phase

N/A

Condition

Stroke

Blood Clots

Cerebral Ischemia

Treatment

Hyperbaric Oxygen Therapy

Clinical Study ID

NCT06148285
Pro00061930.1
  • Ages > 18
  • All Genders

Study Summary

This study will critically examine the feasibility, safety and efficacy of HBOT during inpatient rehabilitation (IPR) after acute ischemic stroke measured by non-disruption of 3 hours of daily therapy, frequency of neurological deterioration or complications (seizure, hemorrhage, brain edema), and functional communication, activities of daily living (ADLs) and mobility.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 18 years and above
  • Ischemic stroke proven on neuroimaging
  • Within 7-30 days post-stroke on day 1 of treatment
  • Admitted to Touro Inpatient Rehab Facility

Exclusion

Exclusion Criteria:

  • Pre-stroke modified Rankin Scale Score >2
  • Parenchymal hemorrhagic transformation (PH1 or PH2)
  • Receptive aphasia such that recommendations for preventative measures to mitigatebarotrauma cannot be followed
  • History of recurrent and unprovoked seizures requiring a change in management in thelast 3 months to control seizures
  • Pulmonary disease requiring supplemental oxygen or daily respiratory medicationmanagement (metered dose inhalers, nebulized treatment or steroids)

Study Design

Total Participants: 120
Treatment Group(s): 1
Primary Treatment: Hyperbaric Oxygen Therapy
Phase:
Study Start date:
May 24, 2022
Estimated Completion Date:
December 31, 2026

Study Description

Preclinical studies support that HBOT augments several adaptive mechanisms following ischemic stroke, including neuroplasticity, cerebral angiogenesis, and regeneration of nerve fibers. The earlier the treatment, the greater potential for a therapeutic effect. However, logistical issues and safety concerns have prevented application of HBOT in the hyperacute window, particularly when coupled with recanalization therapy as the risk of hemorrhagic conversion is highest, monitoring intervals are short, and the natural history is being altered by another treatment. By enrolling patients who are in the subacute phase of stroke who are admitted to an inpatient rehab facility, the risk of HBOT is lower, monitoring intervals are longer, and the selected population has newly acquired and targetable stroke-related disability. Further, the patients are in a supervised setting and available for daily one-hour treatments without disrupting their intensive multidisciplinary rehab plan thereby minimizing nonadherence to daily treatments. Neuroimaging supports that injured, but not dead, brain cells can persist for months after an ischemic event. Hypoxia mediates cellular activity and death through multiple mechanisms. Ongoing decrease in oxygenation to the damaged area due to impaired blood flow works against cellular repair, recovery, and development of new synaptic connections. Increasing oxygen availability has been considered as an obvious treatment for stroke. HBOT has the potential to facilitate the recovery of injured or inactive neurons through increased blood flow and oxygen delivery.

Connect with a study center

  • Touro Infirmary New Orleans

    New Orleans, Louisiana 70112
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.